Fig. 2: Pathologic and genomic characteristics of prostate cancer molecular subtypes.
From: Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype
a–c. Cluster-wise distributions of radical prostatectomy (RP) Gleason score (a), pathologic T (pT) stage (b) and pN stage (c) from the TCGA-PRAD dataset. P values and Q values by chi-square test and Benjamini–Hochberg procedure. d. Kaplan–Meier Plot of Progression-free Survival. Survival data downloaded from cBio-Portal. P value by Log-rank test. f–h. Frequencies of SPOP, TP53, and PIK3CA mutations (e), copy-number alteration events (f), ETS-family fusions (ERG; ETV1, 4, 5, or 6) (g) and TP53 copy-number alteration (CNA) (h). P values and Q values by chi-square test and Benjamini–Hochberg procedure. i, j. Enrichment frequency scatter plot of genome-wide mutations and copy number alteration in between luminal subtype(s) vs. non-luminal subtype(s) of the TCGA-PRAD dataset (i) and the SU2C-PCF 2019 dataset (j). Dot color blue if Q value < 0.05 by chi-square test and Benjamini–Hochberg procedure. k. Frequency of AVPC molecular signature (AVPC-ms) in the clusters of TCGA dataset (upper) and SU2C-PCF dataset (lower). AVPC-ms = two or more of PTEN, TP53 or RB1 mutation/deletion. P values by chi-square test. l. Kaplan–Meier Plot of Progression-free Survival of the SU2C-PCF dataset. Survival data downloaded from cBio-Portal. P value by Log-rank test.
